Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
Anna CorlettoLutz Frankenstein

Abstract

Beta blockers improve survival in patients with chronic systolic heart failure (CHF). Whether physicians should aim for target dose, target heart rate (HR), or both is still under debate. We identified 1,669 patients with systolic CHF due to ischemic heart disease or idiopathic dilated cardiomyopathy from the University Hospital Heidelberg and the Clinic of Ludwigshafen, Germany. All patients were treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker and had a history of CHF known for at least 6 months. Target dose was defined as treatment with ≥ 95% of the respective published guideline-recommended dose. Target HR was defined as 51-69 bpm. All-cause mortality during the median follow-up of 42.8 months was analysed with respect to beta blocker dosing and resting HR. 201 (12%) patients met the dose target (group A), 285 (17.1%) met the HR target (group B), 627 (37.6%) met no target (group C), and 556 (33.3%) did not receive beta blockers (Group D). 5-year mortality was 23.7, 22.7, 37.6, and 55.6% for group A, B, C, and D, respectively (p <  0.001). Survival for group A patients with a HR ≥ 70 bpm was 28.8% but 14.8% if HR was 50-70 bpm (p = 0.054). Achieving guidelines recommended beta blocker d...Continue Reading

References

Apr 1, 1999·European Heart Journal·P AlboniS Scarfò
Jun 2, 2001·The New England Journal of Medicine·M PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival Study Group
Oct 23, 2002·Circulation·Milton PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Apr 14, 2005·European Heart Journal·Michel KomajdaClaude Le Pen
Nov 30, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·F Peters-KlimmJ Szecsenyi
Jun 3, 2009·Annals of Internal Medicine·Finlay A McAlisterPaul W Armstrong
Sep 3, 2010·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Jan-Christian ReilMichael Böhm
Dec 3, 2011·International Journal of Cardiology·Götz GelbrichUNKNOWN CIBIS-ELD investigators
May 12, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Michael BöhmLuigi Tavazzi
May 25, 2012·European Journal of Heart Failure·Damien CullingtonJohn G F Cleland
Sep 11, 2012·Congestive Heart Failure·Helme SilvetAlan K Jacobson
Jun 14, 2013·European Journal of Heart Failure·Bart A MulderUNKNOWN RACE II investigators
May 27, 2014·International Journal of Cardiology·G PoelzlUNKNOWN Austrian Working Group on Heart Failure
Jun 24, 2014·JACC. Heart Failure·Damien CullingtonAndrew L Clark
Sep 16, 2015·Journal of the American Heart Association·Benjamin A SteinbergUNKNOWN Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Investigators and Patients
Sep 19, 2015·Circulation·Tze-Fan ChaoShih-Ann Chen
May 4, 2017·Journal of the American College of Cardiology·Dipak KotechaUNKNOWN Beta-Blockers in Heart Failure Collaborative Group
Oct 19, 2017·European Heart Journal·John G F ClelandUNKNOWN Beta-blockers in Heart Failure Collaborative Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.